Log in or Sign up for Free to view tailored content for your specialty!
Lupus News
Cutaneous complications offer ‘lots of mimickers’ for rheumatologic diseases
DESTIN, Fla. — Dermatomyositis and tinea are just two of many dermatologic complications that may resemble rheumatologic conditions, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.
Insufficient hydroxychloroquine, excessive prednisone may hinder LLDAS, remission in lupus
DESTIN, Fla. — Low disease activity and remission are achievable for patients with lupus if clinicians “minimize the prednisone” and administer adequate hydroxychloroquine, noted a speaker at the 2023 Congress of Clinical Rheumatology-East.
Log in or Sign up for Free to view tailored content for your specialty!
Despite retinopathy concerns, hydroxychloroquine still proven to boost survival in lupus
DESTIN, Fla. — Hydroxychloroquine remains one of the most important drugs in lupus management and should be used as background therapy in nearly all cases, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.
FDA grants fast-track designation to potential CD19-CAR T cell therapy for lupus
The FDA has granted fast-track designation to CABA-201, a CD19-CAR T cell investigational therapy, for the treatment of systemic lupus erythematous and lupus nephritis, according to a press release from the manufacturer.
Patients with pulmonary arterial hypertension with CTD exhibit 59% 10-year survival rate
Patients with pulmonary arterial hypertension associated with connective tissue disease demonstrate a “poor” 10-year rate of 59.9%, according to data published in Rheumatology.
Anti-SSA/RO antibodies predict adverse pregnancy outcomes
The presence of anti-SSA/RO antibodies in pregnant patients can predict adverse pregnancy outcomes, including spontaneous abortion, according to data published in Pediatric Rheumatology.
Baricitinib produces mixed results in pair of BRAVE lupus trials
Baricitinib met the primary endpoint in one phase 3 study of patients with systemic lupus erythematosus, but failed to meet the same endpoint in a second trial aiming to repeat the results, according to data published in The Lancet.
Lupus Research Alliance, FDA partner to counter challenges in lupus drug development
The Lupus Research Alliance and the FDA have announced a public-private partnership to increase collaboration and further the advancement of personalized therapies for lupus.
P. jirovecii pneumonia prophylaxis use in lupus ‘much lower’ than prior studies suggest
The real-world use of Pneumocystis jirovecii pneumonia prophylaxis in patients with systemic lupus erythematous is “much lower” than prior survey-based studies suggest, according to data published in Seminars in Arthritis and Rheumatism.
One-third of lupus hospitalizations lack post-discharge follow-up care
Approximately one-third of lupus hospitalizations lack post-discharge follow-up care, with “significant disparities” reported among rural and disadvantaged localities, according to Medicare data published in Arthritis Care & Research.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read